Newsfeeds - Spark Newswire

1 minute read

Capricor Therapeutics Announces 18-Month Results From Ongoing HOPE-2 Open Label Extension Study Of CAP-1002 In Duchenne Muscular Dystrophy Patients

Today, 4:53 PM

-Statistically Significant Results in Performance of the Upper Limb PUL 2.0 (p=0.02) Extended to 18 Months, Demonstrating Long-Term Benefit in Skeletal Muscle Function- -Results Continue to Suggest Potential

CAPR

1 minute read

Capricor Highlights Preclinical Data From Its Closed COVID-19 Vaccine Study

By Vandana Singh

Today, 4:53 PM

Capricor Therapeutics (NASDAQ:CAPR) announced the publication of a preclinical study online in bioRxiv and explored Capricor’s proprietary StealthX exosome platform’s therapeutic potential, generating…

CAPR

2 minute read

Capricor Announces Publication Highlighting New Advances For Its Engineered Exosome Platform

By Benzinga Newsdesk

Today, 4:53 PM

-StealthX™Exosome Platform Shows Multivalent Vaccine Induces Long-Lasting Immunity to Multiple SARS-CoV-2 Proteins- SAN DIEGO, Jan. 12, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR)

CAPR

8 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For October 26, 2022

By Benzinga Insights

Today, 4:53 PM

Upgrades

ABT

1 minute read

Ladenburg Thalmann Initiates Coverage On Capricor Therapeutics with Buy Rating, Announces Price Target of $15

By Benzinga Newsdesk

Today, 4:53 PM

Ladenburg Thalmann analyst Aydin Huseynov initiates coverage on Capricor Therapeutics (NASDAQ:CAPR) with a Buy rating and announces Price Target of $15.

CAPR

11 minute read

Earnings Scheduled For August 10, 2022

By Benzinga Insights

Today, 4:53 PM

Companies Reporting Before The Bell • Wix.com (NASDAQ:WIX) is estimated to report earnings for its second quarter.

AADI

4 minute read

Recap of Tuesday’s Biotech Catalysts – End Of The Day Summary

By Ragothaman Srinivasan

Today, 4:53 PM

The U.S. Food and Drug Administration (FDA) has granted tentative approval to Avadel Pharmaceuticals’ (NASDAQ: AVDL) lead candidate LUMRYZ (FT218) for the treatment of excessive daytime sleepiness (EDS) or cataplexy in adults with narcolepsy.

ALNA

2 minute read

FDA
News

Capricor Therapeutics Announces First Patient Dosed In Pivotal Phase 3 Study Of CAP-1002 For Treatment Of Duchenne Muscular Dystrophy

By Benzinga Newsdesk

Today, 4:53 PM

Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select

CAPR

2 minute read

More Than $27 Million Bet On Seres Therapeutics? 4 Penny Stocks Insiders are Buying

By Lisa Levin

Today, 4:53 PM

U.S. stock futures traded lower this morning on Friday ahead of jobs report for june. Investors, meanwhile, focused on some notable insider trades.

CAPR

20 minute read

Earnings Scheduled For May 10, 2022

By Benzinga Insights

Today, 4:53 PM

Companies Reporting Before The Bell • The Middleby (NASDAQ:MIDD) is expected to report quarterly earnings at $2.10 per share on revenue of $935.99 million.

ABCL